Author: admin

“Nerve Growth Factor Market”

Nerve Growth Factor therapies are expected to boost the Nerve Growth Factor Market in the upcoming years.

DelveInsight has launched a new report on “Nerve Growth Factor – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Nerve Growth Factor, historical and forecasted epidemiology as well as the Nerve Growth Factor market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Request for a detailed report @ https://www.delveinsight.com/sample-request/nerve-growth-factor-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Nerve Growth Factor Market Report:

• Zhao et al. (2022) reported that osteoarthritis (OA) is the third leading cause of disability, affecting around 350 million people globally. Nerve growth factor (NGF) plays a role in pain signal transmission and nociceptor receptor gene expression, acting as a nociceptor sensitizer. It has been explored as a potential target for OA pain treatment. The study found that the risk of rapidly progressive OA at the final follow-up ranged from 0.7% to 6.3% with anti-NGF monoclonal antibody treatment, compared to 0.2% to 1.2% with the active comparator (overall 4.4% vs. 0.8%).

• Key Nerve Growth Factor companies such as Dompé farmaceutici S.p.A., Pfizer Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Merck KGaA, Sanofi, Promega Corporation, and Alomone Labs, and others are evaluating new drugs for Nerve Growth Factor to improve the treatment landscape.

• In October 2023, the FDA granted Fast Track designation to NVG-291, a therapeutic peptide targeting nervous system repair mechanisms, for treating individuals with spinal cord injuries. This designation aims to expedite the development and review process for drugs addressing serious conditions with unmet medical needs.

Key benefits of the Nerve Growth Factor market report:

1. Nerve Growth Factor market report covers a descriptive overview and comprehensive insight of the Nerve Growth Factor Epidemiology and Nerve Growth Factor market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Nerve Growth Factor market report provides insights on the current and emerging therapies.

3. Nerve Growth Factor market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Nerve Growth Factor market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Nerve Growth Factor market.

Got queries? Click here to know more about the Nerve Growth Factor Market Landscape

Nerve Growth Factor Overview

Nerve Growth Factor (NGF), a type of neurotrophin, is vital for the proper functioning of the nervous, immune, and endocrine systems. As the first neurotrophin to be discovered, NGF is essential for neural development, differentiation, and maintenance in both the central (CNS) and peripheral nervous systems (PNS) throughout life. It is a pleiotropic molecule, produced and utilized by a variety of cell types, including both structural and immune cells.

NGF exerts its effects via two main receptors: the high-affinity trkANGFR, which possesses tyrosine kinase activity, and the low-affinity p75NTR, a pan-neurotrophin receptor. While trkANGFR generally promotes cell survival and growth, p75NTR can trigger apoptotic pathways when trkANGFR levels are low. The interplay between these receptors determines NGF’s overall influence on target cells.

Impaired NGF transport can result in nerve damage, as observed in peripheral neuropathies. NGF and its receptors are also implicated in tumor cell proliferation, differentiation, and migration in various cancers. Moreover, NGF plays a central role as a mediator of peripheral pain.

Nerve Growth Factor Market Outlook

The Nerve Growth Factor market is expected to evolve significantly in the coming years, driven by the anticipated introduction of emerging therapies from leading companies such as Dompé farmaceutici S.p.A., Pfizer Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Merck KGaA, Sanofi, Promega Corporation, Alomone Labs, and others during the forecast period 2020–2034.

Discover how the nerve growth factor market is rising in the upcoming years

Nerve Growth Factor Companies: Dompé farmaceutici S.p.A., Pfizer Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Merck KGaA, Sanofi, Promega Corporation, and Alomone Labs, and others.

Scope of the Nerve Growth Factor Market Report

• Study Period: 2020-2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Nerve Growth Factor Companies: Dompé farmaceutici S.p.A., Pfizer Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Merck KGaA, Sanofi, Promega Corporation, and Alomone Labs, and others

• Nerve Growth Factor Therapeutic Assessment: Nerve Growth Factor current marketed and Nerve Growth Factor emerging therapies

• Nerve Growth Factor Market Dynamics: Nerve Growth Factor market drivers and Nerve Growth Factor market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Nerve Growth Factor Unmet Needs, KOL’s views, Analyst’s views, Nerve Growth Factor Market Access and Reimbursement

Request for our free sample pages @ https://www.delveinsight.com/report-store/nerve-growth-factor-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Nerve Growth Factor Patient Share (%) Overview at a Glance

5. Nerve Growth Factor Market Overview at a Glance

6. Nerve Growth Factor Disease Background and Overview

7. Nerve Growth Factor Epidemiology and Patient Population

8. Country-Specific Patient Population of Nerve Growth Factor

9. Nerve Growth Factor Current Treatment and Medical Practices

10. Unmet Needs

11. Nerve Growth Factor Emerging Therapies

12. Nerve Growth Factor Market Outlook

13. Country-Wise Nerve Growth Factor Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Nerve Growth Factor Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Nerve Growth Factor Pipeline Insights, DelveInsight

“Nerve Growth Factor Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Nerve Growth Factor market. A detailed picture of the Nerve Growth Factor pipeline landscape is provided, which includes the disease overview and Nerve Growth Factor treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nerve Growth Factor Market: Epidemiology, Therapies, Companies, DelveInsight | Dompé farmaceutici S.p.A., Pfizer Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Merck KGaA, Sanofi, Promega

“Sezary Syndrome Clinical Trials”

DelveInsight reports that over five key companies are actively developing more than five therapeutic candidates for Sezary Syndrome.

Sezary Syndrome Overview:

Sezary Syndrome is a highly aggressive form of cutaneous T-cell lymphoma, a group of disorders in which T-cells (a type of white blood cell) become malignant and affect the skin. It is characterized by a widespread red rash, the presence of malignant T-cells known as Sezary cells in the blood, and enlarged lymph nodes.

Other symptoms may include intense itching, skin scaling and peeling, fever, weight loss, hair loss, outward turning of the eyelids (ectropion), thickened skin on the palms and soles (palmoplantar keratoderma), nail changes, and enlargement of the liver or spleen (hepatosplenomegaly).

The exact cause of Sezary Syndrome remains largely unknown. While a small number of cases are associated with human T-lymphotropic viruses types 1 and 2, most cases have no identified cause. Diagnosis is usually suspected based on distinctive clinical signs and confirmed through additional tests.

Treatment is individualized according to symptoms and disease severity and may include photodynamic therapy, radiation therapy, chemotherapy, topical or systemic drug therapies (e.g., steroids or retinoids), biologic therapies, and targeted treatments.

Request for a detailed insights report on Sezary Syndrome pipeline insights

“Sezary Syndrome Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Sezary Syndrome Therapeutics Market.

Key Takeaways from the Sezary Syndrome Pipeline Report

• DelveInsight’s Sezary Syndrome pipeline report highlights an active landscape with over five companies developing more than five therapeutic candidates for Sezary Syndrome treatment.

• In February 2025, the U.S. FDA granted Breakthrough Therapy Designation to lacutamab, an anti-KIR3DL2 antibody developed by Innate Pharma, based on promising Phase 1 and 2 trial results demonstrating both efficacy and a favorable safety profile in patients with relapsed or refractory Sézary Syndrome who had previously received treatments including mogamulizumab. Lacutamab had earlier received Fast Track designation in 2019 and PRIME designation from the EMA in 2020.

• Key players such as 4SC AG, Seagen Inc., Merck Sharp & Dohme Corp., Innate Pharma, Trillium Therapeutics, Secura Bio, and others are actively evaluating new therapies to enhance the Sezary Syndrome treatment landscape.

• Promising pipeline candidates in development include Lacutamab, Resminostat, and others at various stages of clinical evaluation.

Sezary Syndrome Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Sezary Syndrome Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sezary Syndrome treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Sezary Syndrome market.

Download our free sample page report on Sezary Syndrome pipeline insights

Sezary Syndrome Emerging Drugs

• Lacutamab: Innate Pharma

• Resminostat: 4SC

Sezary Syndrome Companies

Approximately five leading companies are developing therapies for Sezary Syndrome, with Innate Pharma advancing the most progressed candidates, currently in Phase II clinical trials.

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Sezary Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Sezary Syndrome Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Sezary Syndrome Therapies and Key Companies: Sezary Syndrome Clinical Trials and advancements

Sezary Syndrome Pipeline Therapeutic Assessment

• Sezary Syndrome Assessment by Product Type

• Sezary Syndrome By Stage

• Sezary Syndrome Assessment by Route of Administration

• Sezary Syndrome Assessment by Molecule Type

Download Sezary Syndrome Sample report to know in detail about the Sezary Syndrome treatment market @ Sezary Syndrome Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Sezary Syndrome Current Treatment Patterns

4. Sezary Syndrome – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Sezary Syndrome Late-Stage Products (Phase-III)

7. Sezary Syndrome Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Sezary Syndrome Discontinued Products

13. Sezary Syndrome Product Profiles

14. Sezary Syndrome Key Companies

15. Sezary Syndrome Key Products

16. Dormant and Discontinued Products

17. Sezary Syndrome Unmet Needs

18. Sezary Syndrome Future Perspectives

19. Sezary Syndrome Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Sezary Syndrome Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sezary Syndrome Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | 4SC AG, Seagen Inc., Merck Sharp & Dohme Corp., Innate Pharma, Trillium Therapeutics, Sec

“HER2 Negative Metastatic Breast Cancer Clinical Trials”

DelveInsight reports that over 50 key companies are actively developing more than 50 therapeutic candidates for HER2-negative metastatic breast cancer.

HER2 Negative Metastatic Breast Cancer Overview:

Breast cancer is the most prevalent cancer among women worldwide and remains a leading cause of mortality. At diagnosis, about 5% of patients present with distant metastases, while roughly 30% of early-stage cases eventually progress to metastatic disease. Although metastatic breast cancer cannot be completely cured, advances in therapy have considerably improved survival rates and quality of life (QoL). Treatment primarily aims to prolong survival and manage symptoms, with strategies tailored to each patient rather than using a uniform approach.

HER2-negative breast cancer is a subtype in which cancer cells do not overexpress the HER2 protein, a key factor in cell growth. It is further divided based on hormone receptor (HR) status. HR-positive breast cancer, accounting for 50–70% of cases, depends on hormones like estrogen or progesterone for growth. Triple-negative breast cancer (TNBC) lacks both HER2 and hormone receptors, making it more challenging to treat.

For HER2-negative metastatic breast cancer, the focus is on disease management rather than cure, aiming to extend survival and improve QoL. Standard treatments include:

• Hormonal (endocrine) therapy, which blocks estrogen effects to slow tumor growth and generally causes fewer side effects than chemotherapy.

• Chemotherapy, used alone or in combination with other drugs to destroy cancer cells.

• Targeted therapy (precision medicine), an emerging approach that inhibits specific molecules driving cancer progression.

In addition to active treatment, palliative care can help manage pain, anxiety, and other symptoms associated with advanced breast cancer. Because metastatic disease affects patients differently, personalized treatment plans are essential to optimize outcomes and enhance overall well-being.

Request for a detailed insights report on HER2 Negative Metastatic Breast Cancer pipeline insights

“HER2 Negative Metastatic Breast Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the HER2 Negative Metastatic Breast Cancer Therapeutics Market.

Key Takeaways from the HER2 Negative Metastatic Breast Cancer Pipeline Report

• DelveInsight’s HER2-Negative Metastatic Breast Cancer (MBC) pipeline report highlights a vibrant landscape with over 50 companies developing more than 50 therapeutic candidates for HER2-negative MBC.

• In March 2025, the VERITAC-2 trial showed that vepdegestrant (ARV-471) significantly improved progression-free survival compared to fulvestrant in patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations, underscoring its potential as a promising therapy pending further evaluation and FDA approval.

• In January 2025, the FDA approved datopotamab deruxtecan-dlnk (Datroway) for adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who had previously received endocrine therapy and chemotherapy. This approval was supported by the TROPION-Breast01 trial, which demonstrated significant efficacy in this population.

• In October 2024, the FDA approved inavolisib in combination with palbociclib and fulvestrant for adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer, based on results from the INAVO120 trial showing notable efficacy.

• Key players such as BeiGene, Context Therapeutics, Astex Pharmaceuticals, Eisai Inc., AstraZeneca, Dantari, Inc., and others are actively advancing new therapies to enhance the HER2-negative MBC treatment landscape.

• Promising pipeline candidates in various stages include Pamiparib, Onapristone, and others.

HER2 Negative Metastatic Breast Cancer Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the HER2 Negative Metastatic Breast Cancer Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2 Negative Metastatic Breast Cancer treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the HER2 Negative Metastatic Breast Cancer market.

Download our free sample page report on HER2 Negative Metastatic Breast Cancer pipeline insights

HER2 Negative Metastatic Breast Cancer Emerging Drugs

• Pamiparib: BeiGene

• Onapristone: Context Therapeutics

HER2 Negative Metastatic Breast Cancer Companies

Over 50 major pharmaceutical companies are actively developing therapies for HER2-negative metastatic breast cancer, with BeiGene advancing the most progressed candidate, currently in Phase II clinical trials.

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

HER2 Negative Metastatic Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

HER2 Negative Metastatic Breast Cancer Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging HER2 Negative Metastatic Breast Cancer Therapies and Key Companies: HER2 Negative Metastatic Breast Cancer Clinical Trials and advancements

HER2 Negative Metastatic Breast Cancer Pipeline Therapeutic Assessment

• HER2 Negative Metastatic Breast Cancer Assessment by Product Type

• HER2 Negative Metastatic Breast Cancer By Stage

• HER2 Negative Metastatic Breast Cancer Assessment by Route of Administration

• HER2 Negative Metastatic Breast Cancer Assessment by Molecule Type

Download HER2 Negative Metastatic Breast Cancer Sample report to know in detail about the HER2 Negative Metastatic Breast Cancer treatment market @ HER2 Negative Metastatic Breast Cancer Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. HER2 Negative Metastatic Breast Cancer Current Treatment Patterns

4. HER2 Negative Metastatic Breast Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. HER2 Negative Metastatic Breast Cancer Late-Stage Products (Phase-III)

7. HER2 Negative Metastatic Breast Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. HER2 Negative Metastatic Breast Cancer Discontinued Products

13. HER2 Negative Metastatic Breast Cancer Product Profiles

14. HER2 Negative Metastatic Breast Cancer Key Companies

15. HER2 Negative Metastatic Breast Cancer Key Products

16. Dormant and Discontinued Products

17. HER2 Negative Metastatic Breast Cancer Unmet Needs

18. HER2 Negative Metastatic Breast Cancer Future Perspectives

19. HER2 Negative Metastatic Breast Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the HER2 Negative Metastatic Breast Cancer Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HER2 Negative Metastatic Breast Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | BeiGene, Context Therapeutics, Astex Pharmaceuticals, Eisai Inc.,

“Gorlin Syndrome Clinical Trials”

DelveInsight reports that over five key companies are actively developing more than five therapeutic candidates for Gorlin Syndrome.

Gorlin Syndrome Overview:

Gorlin syndrome is a rare genetic disorder that affects multiple organs and tissues. Individuals with this condition have a substantially increased risk of developing basal cell carcinoma during adolescence or early adulthood and are also more susceptible to medulloblastoma (a type of brain cancer) and other malignancies. The syndrome can also cause benign tumors in the jaw, heart, or ovaries.

Common features include a larger head size, distinctive facial characteristics, small pits in the skin of the hands and feet, spinal, rib, or skull abnormalities, eye problems, and developmental delays. Gorlin syndrome is caused by mutations in the PTCH1 gene and is also referred to as basal cell nevus syndrome (BCNS), NBCCS, or nevoid basal cell carcinoma syndrome.

Request for a detailed insights report on Gorlin Syndrome pipeline insights

“Gorlin Syndrome Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Gorlin Syndrome Therapeutics Market.

Key Takeaways from the Gorlin Syndrome Pipeline Report

• DelveInsight’s Gorlin Syndrome pipeline report highlights an active landscape with over five companies developing more than five therapeutic candidates for Gorlin Syndrome.

• In August 2024, Inhibitor Therapeutics reported progress on a novel itraconazole formulation aimed at treating Basal Cell Carcinomas (BCC) in Gorlin Syndrome patients, offering new hope for managing this rare genetic condition.

• Key players such as Palvella Therapeutics, PellePharm, Ascend Biopharmaceuticals, and others are actively evaluating new therapies to enhance the Gorlin Syndrome treatment landscape.

• Promising pipeline candidates in development include PTX-022 and others in various stages of clinical evaluation.

Gorlin Syndrome Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Gorlin Syndrome Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gorlin Syndrome treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Gorlin Syndrome market.

Download our free sample page report on Gorlin Syndrome pipeline insights

Gorlin Syndrome Emerging Drugs

• PTX-022: Palvella Therapeutics

Gorlin Syndrome Companies

Around five leading companies are developing therapies for Gorlin syndrome, with Palvella Therapeutics advancing the most progressed candidates, currently in Phase II clinical trials.

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Gorlin Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Gorlin Syndrome Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Gorlin Syndrome Therapies and Key Companies: Gorlin Syndrome Clinical Trials and advancements

Gorlin Syndrome Pipeline Therapeutic Assessment

• Gorlin Syndrome Assessment by Product Type

• Gorlin Syndrome By Stage

• Gorlin Syndrome Assessment by Route of Administration

• Gorlin Syndrome Assessment by Molecule Type

Download Gorlin Syndrome Sample report to know in detail about the Gorlin Syndrome treatment market @ Gorlin Syndrome Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Gorlin Syndrome Current Treatment Patterns

4. Gorlin Syndrome – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Gorlin Syndrome Late-Stage Products (Phase-III)

7. Gorlin Syndrome Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Gorlin Syndrome Discontinued Products

13. Gorlin Syndrome Product Profiles

14. Gorlin Syndrome Key Companies

15. Gorlin Syndrome Key Products

16. Dormant and Discontinued Products

17. Gorlin Syndrome Unmet Needs

18. Gorlin Syndrome Future Perspectives

19. Gorlin Syndrome Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Gorlin Syndrome Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gorlin Syndrome Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Palvella Therapeutics, Inc, PellePharm, Ascend Biopharmaceuticals

“Refractory Metastatic Melanoma Clinical Trials”

DelveInsight reports that over four key companies are actively developing more than four therapeutic candidates for Refractory Metastatic Melanoma.

Refractory Metastatic Melanoma Overview:

Refractory metastatic melanoma is a type of melanoma that does not respond to standard therapies such as chemotherapy, radiation, or early targeted treatments. Despite advancements with targeted therapy combinations and immunotherapies, metastatic melanoma remains highly aggressive, and prognosis worsens once it spreads beyond the skin. While early-stage melanoma generally has a high survival rate, metastasis—particularly to critical sites like the central nervous system (CNS)—poses significant treatment challenges due to the tumor’s ability to evade immune detection and cross the blood-brain barrier. The complexity of metastatic melanoma is further influenced by genetic alterations, including MITF amplification, TERT promoter mutations, and CDKN2A loss, which are more prevalent in metastatic cases, though the exact mechanisms driving metastasis remain incompletely understood.

Melanoma’s aggressive nature is fueled by a combination of genetic mutations and environmental factors. The BRAF V600E mutation, present in 40–50% of cutaneous melanomas, plays a key role in tumor progression by activating the MAPK pathway. UV radiation is a major environmental factor contributing to melanoma, causing DNA damage in melanocytes, the cells responsible for melanin production and the origin of melanoma. Despite progress in immunotherapy and targeted therapies, resistance and disease relapse remain major hurdles, highlighting the need for continued research into melanoma biology.

Request for a detailed insights report on Refractory Metastatic Melanoma pipeline insights

“Refractory Metastatic Melanoma Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Refractory Metastatic Melanoma Therapeutics Market.

Key Takeaways from the Refractory Metastatic Melanoma Pipeline Report

• DelveInsight’s Refractory Metastatic Melanoma (RMM) pipeline report highlights a dynamic landscape with over four companies developing more than four therapeutic candidates for RMM treatment.

• On March 31, 2025, the FDA granted Breakthrough Therapy Designation to darovasertib, a protein kinase C inhibitor, as a neoadjuvant therapy for primary uveal melanoma, a rare melanoma subtype.

• In February 2024, the FDA granted accelerated approval to lifileucel, a tumor-infiltrating lymphocyte (TIL) therapy, for adults with unresectable or metastatic melanoma who have previously received certain treatments.

• Key players such as BioNTech SE, Y-mAbs Therapeutics, Seagen Inc., and others are actively evaluating new therapies to advance the treatment landscape for RMM.

• Promising pipeline candidates in various stages of development include BNT111, GD2-SADA, and others.

Refractory Metastatic Melanoma Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Refractory Metastatic Melanoma Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Refractory Metastatic Melanoma treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Refractory Metastatic Melanoma market.

Download our free sample page report on Refractory Metastatic Melanoma pipeline insights

Refractory Metastatic Melanoma Emerging Drugs

• BNT111: BioNTech SE

• GD2-SADA: Y-mAbs Therapeutics

Refractory Metastatic Melanoma Companies

Around four leading companies are developing therapies for refractory metastatic melanoma, with BioNTech SE advancing the most progressed candidates, currently in Phase II clinical trials.

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Refractory Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Refractory Metastatic Melanoma Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Refractory Metastatic Melanoma Therapies and Key Companies: Refractory Metastatic Melanoma Clinical Trials and advancements

Refractory Metastatic Melanoma Pipeline Therapeutic Assessment

• Refractory Metastatic Melanoma Assessment by Product Type

• Refractory Metastatic Melanoma By Stage

• Refractory Metastatic Melanoma Assessment by Route of Administration

• Refractory Metastatic Melanoma Assessment by Molecule Type

Download Refractory Metastatic Melanoma Sample report to know in detail about the Refractory Metastatic Melanoma treatment market @ Refractory Metastatic Melanoma Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Refractory Metastatic Melanoma Current Treatment Patterns

4. Refractory Metastatic Melanoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Refractory Metastatic Melanoma Late-Stage Products (Phase-III)

7. Refractory Metastatic Melanoma Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Refractory Metastatic Melanoma Discontinued Products

13. Refractory Metastatic Melanoma Product Profiles

14. Refractory Metastatic Melanoma Key Companies

15. Refractory Metastatic Melanoma Key Products

16. Dormant and Discontinued Products

17. Refractory Metastatic Melanoma Unmet Needs

18. Refractory Metastatic Melanoma Future Perspectives

19. Refractory Metastatic Melanoma Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Refractory Metastatic Melanoma Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Refractory Metastatic Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | BioNTech SE, Y-mAbs Therapeutics, Seagen Inc.

“Chemotherapy Induced Febrile Neutropenia Clinical Trials”

DelveInsight reports that more than four key companies are actively developing over four therapeutic candidates for Chemotherapy-Induced Febrile Neutropenia (CIFN).

Chemotherapy Induced Febrile Neutropenia Overview:

Chemotherapy-Induced Febrile Neutropenia (CIN) is a major dose-limiting complication for cancer patients receiving chemotherapy. It can result in febrile neutropenia (FN) and is associated with increased morbidity, early mortality, higher healthcare costs, and interruptions to essential cancer treatments. The risk and severity of CIN, including complications like fever, infections, and chemotherapy dose modifications, vary by cancer type. According to a large prospective registry, CIN occurred in 15% to 65% of patients across five major cancers—breast, colon, lymphoma, lung, and ovarian—while the incidence of FN ranged from 7% to 30%.

Request for a detailed insights report on Chemotherapy Induced Febrile Neutropenia pipeline insights

“Chemotherapy Induced Febrile Neutropenia Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chemotherapy Induced Febrile Neutropenia Therapeutics Market.

Key Takeaways from the Chemotherapy Induced Febrile Neutropenia Pipeline Report

• DelveInsight’s Chemotherapy-Induced Febrile Neutropenia (CIN) pipeline report highlights an active landscape with over four companies developing more than four therapeutic candidates for CIN treatment.

• Ryzneuta, approved in November 2023, is a long-acting G-CSF indicated to reduce the risk of infection, as manifested by febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy.

• Rolvedon, approved in September 2022, is another long-acting G-CSF designed to decrease the incidence of infection, as manifested by febrile neutropenia, in adults undergoing myelosuppressive chemotherapy.

• Key players such as BeyondSpring Pharmaceuticals, Enzychem Lifesciences, Tianjin SinoBiotech Ltd., Evive Biotech, and others are actively evaluating new therapies to improve the CIN treatment landscape.

• Promising pipeline candidates in development include Plinabulin, EC-18, and others in various stages of clinical evaluation.

Chemotherapy Induced Febrile Neutropenia Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Chemotherapy Induced Febrile Neutropenia Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chemotherapy Induced Febrile Neutropenia treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chemotherapy Induced Febrile Neutropenia market.

Download our free sample page report on Chemotherapy Induced Febrile Neutropenia pipeline insights

Chemotherapy Induced Febrile Neutropenia Emerging Drugs

• Plinabulin: BeyondSpring Pharmaceuticals

• EC-18: Enzychem Lifesciences

Chemotherapy Induced Febrile Neutropenia Companies

Approximately four leading companies are developing therapies for chemotherapy-induced febrile neutropenia, with BeyondSpring Pharmaceuticals advancing the most progressed candidates, currently at the preregistration stage.

DelveInsight’s report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Chemotherapy Induced Febrile Neutropenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Chemotherapy Induced Febrile Neutropenia Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Chemotherapy Induced Febrile Neutropenia Therapies and Key Companies: Chemotherapy Induced Febrile Neutropenia Clinical Trials and advancements

Chemotherapy Induced Febrile Neutropenia Pipeline Therapeutic Assessment

• Chemotherapy Induced Febrile Neutropenia Assessment by Product Type

• Chemotherapy Induced Febrile Neutropenia By Stage

• Chemotherapy Induced Febrile Neutropenia Assessment by Route of Administration

• Chemotherapy Induced Febrile Neutropenia Assessment by Molecule Type

Download Chemotherapy Induced Febrile Neutropenia Sample report to know in detail about the Chemotherapy Induced Febrile Neutropenia treatment market @ Chemotherapy Induced Febrile Neutropenia Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Chemotherapy Induced Febrile Neutropenia Current Treatment Patterns

4. Chemotherapy Induced Febrile Neutropenia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Chemotherapy Induced Febrile Neutropenia Late-Stage Products (Phase-III)

7. Chemotherapy Induced Febrile Neutropenia Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chemotherapy Induced Febrile Neutropenia Discontinued Products

13. Chemotherapy Induced Febrile Neutropenia Product Profiles

14. Chemotherapy Induced Febrile Neutropenia Key Companies

15. Chemotherapy Induced Febrile Neutropenia Key Products

16. Dormant and Discontinued Products

17. Chemotherapy Induced Febrile Neutropenia Unmet Needs

18. Chemotherapy Induced Febrile Neutropenia Future Perspectives

19. Chemotherapy Induced Febrile Neutropenia Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Chemotherapy Induced Febrile Neutropenia Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chemotherapy Induced Febrile Neutropenia Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | BeyondSpring Pharmaceuticals, Enzychem Lifesciences, Tianjin Sin

“Equine Encephalitis Clinical Trials”

DelveInsight reports that over five key companies are actively developing more than five therapeutic candidates for Equine Encephalitis.

Equine Encephalitis Overview:

Western, Eastern, and Venezuelan equine encephalitis viruses vary in infection rates and severity, but all can produce flu-like symptoms, neurological complications, and in some cases, fatal outcomes. These viruses are transmitted to humans via mosquito bites, and approximately 5% of infections can progress to the rare but serious condition of encephalitis. In the United States, cases of Eastern equine encephalitis (Triple E) have been increasing, with the CDC reporting nearly 40 cases and 15 deaths in 2019, marking the largest recorded outbreak. Currently, no vaccines are approved for any of the equine encephalitis viruses.

Request for a detailed insights report on Equine Encephalitis pipeline insights

“Equine Encephalitis Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Equine Encephalitis Therapeutics Market.

Key Takeaways from the Equine Encephalitis Pipeline Report

• DelveInsight’s Equine Encephalitis (EE) pipeline report highlights a dynamic landscape with over five companies developing more than five therapeutic candidates for EE.

• Key players such as Bavarian Nordic, Merck & Co, Ridgeback Biotherapeutics, AlphaVax, Mapp Biopharmaceutical, and others are advancing new drugs to enhance treatment options for equine encephalitis.

• Promising pipeline candidates in various stages of development include MVA-BN® WEV, Molnupiravir, and others.

Bavarian Nordic’s MVA-BN WEV Vaccine:

• Phase 1 Clinical Trial: The company completed a Phase 1 trial for the MVA-BN WEV vaccine, a trivalent recombinant Modified Vaccinia Ankara-based vaccine targeting Western, Eastern, and Venezuelan equine encephalitis viruses. The trial showed the vaccine was well-tolerated and immunogenic, eliciting neutralizing antibody responses against all three viruses across different dose groups.

• Phase 2 Plans: Based on these encouraging results, Bavarian Nordic plans to initiate a Phase 2 dose-finding study in 2025 to further assess the vaccine’s safety and efficacy.

Equine Encephalitis Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Equine Encephalitis Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Equine Encephalitis treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Equine Encephalitis market.

Download our free sample page report on Equine Encephalitis pipeline insights

Equine Encephalitis Emerging Drugs

• MVA-BN® WEV: Bavarian Nordic

• Molnupiravir: Ridgeback Biotherapeutics/Merck

Equine Encephalitis Companies

Over five leading companies are actively working on therapies for equine encephalitis, with Bavarian Nordic advancing the most progressed candidates, currently in Phase I clinical trials.

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Equine Encephalitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Equine Encephalitis Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Equine Encephalitis Therapies and Key Companies: Equine Encephalitis Clinical Trials and advancements

Equine Encephalitis Pipeline Therapeutic Assessment

• Equine Encephalitis Assessment by Product Type

• Equine Encephalitis By Stage

• Equine Encephalitis Assessment by Route of Administration

• Equine Encephalitis Assessment by Molecule Type

Download Equine Encephalitis Sample report to know in detail about the Equine Encephalitis treatment market @ Equine Encephalitis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Equine Encephalitis Current Treatment Patterns

4. Equine Encephalitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Equine Encephalitis Late-Stage Products (Phase-III)

7. Equine Encephalitis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Equine Encephalitis Discontinued Products

13. Equine Encephalitis Product Profiles

14. Equine Encephalitis Key Companies

15. Equine Encephalitis Key Products

16. Dormant and Discontinued Products

17. Equine Encephalitis Unmet Needs

18. Equine Encephalitis Future Perspectives

19. Equine Encephalitis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Equine Encephalitis Pipeline Reports Offerings

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Equine Encephalitis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline | Bavarian Nordic, Merck & Co, Ridgeback Biotherapeutics, AlphaVax, Mapp Biopharmaceuti